ArticleLife (Basel, Switzerland)2025
Remodeling of Gut Microbial Networks After Sulforaphane Supplementation in Patients with Chronic Kidney Disease.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multi-omics analysis identifies microbial dysbiosis and functional metabolic reprogramming in acute kidney injury.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
objectivesChronic kidney disease (CKD) is closely associated with gut dysbiosis, and sulforaphane (SFN), a bioactive compound found in cruciferous vegetables, may help to mitigate this condition.
methodsThese are secondary exploratory analyses from a previous study that included 16 patients with CKD (stages 3 to 5). The patients were divided into two groups: the Sulforaphane (SFN) group (400 mcg/day of SFN) and the placebo group, both of which received treatment for four weeks. Fecal DNA extraction was performed, and amplicon sequencing was conducted on an Illumina MiSeq V3 platform. The sequence data were analyzed using the QIIME 2 software package. Plasma uremic toxin concentrations (indoxyl sulfate, IS, and p-cresyl sulfate, pCS) were measured by HPLC with fluorescence detection.
resultsNo significant differences were observed in the gut microbiota alpha microbial richness and diversity after supplementation. However, supplementation with SFN altered the taxonomic composition and resulted in changes to the complexity of the microbial network. A distinct set of Amplicon Sequence Variants (ASVs) was observed post-supplementation with SFN, dominated by genera such as
conclusionsSFN supplementation for one month did not significantly alter microbial diversity or uremic toxin levels in non-dialysis CKD patients; however, it led to changes in microbial composition and network complexity, suggesting a modulatory effect on specific microbial interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.